Updates

January 18, 2021January 18, 2021
Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The findings suggest that an ... Read more
January 14, 2021January 14, 2021
Genetic Test for Advanced Breast Cancer Launched in EU

Roche has launched a diagnostic genetic test to detect mutations in the PIK3CA gene in patients with advanced or metastatic breast cancer in the European ... Read more
January 11, 2021January 11, 2021
Breast Cancer Vaccine Cleared by FDA for Human Testing

A breast cancer vaccine can now be tested in human trials after its investigational new drug application was accepted by the U.S. Food and ... Read more
January 7, 2021January 7, 2021
ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers

ARX788 has been given a fast track designation by the U.S. Food and Drug Administration as a monotherapy for patients with HER2-positive metastatic breast ... Read more
January 4, 2021January 4, 2021
Conditional Approval Urged in EU for Trastuzumab Deruxtecan

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended the conditional approval of trastuzumab deruxtecan (DS-8201) for the treatment of ... Read more

Subscribe to our mailing list

Get regular updates delivered to your email box.

Thanks! Please check your email for a confirmation email.

June 22, 2018June 22, 2018

Clinical Trial of Tamoxifen-based Gel in Reducing Breast Density Recruiting in US, EU

News

The ability of a gel containing a tamoxifen-byproduct to reduce breast density — associated with an increased risk of breast cancer — is now being evaluated in a recruiting Phase 3 clinical trial. Approximately half of women in ... Read more

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

Genetic Test for Advanced Breast Cancer Launched in EU

Breast Cancer Vaccine Cleared by FDA for Human Testing

ARX788 on FDA Fast Track for Advanced HER2-positive Breast Cancers

Conditional Approval Urged in EU for Trastuzumab Deruxtecan

Margenza Approved in US for Pretreated HER2-positive Breast Cancer

Antibody-drug Combo Shows Early Promise in Targeting Cancers, Company Says

Computer Model Uses Enzyme Organization to Predict Early Breast Cancer Recurrence

‘Unassuming’ Non-medicinal Plant Can Stop Growth of Breast Cancer Cells, Study Shows

Onconova Seeking FDA Approval for Phase 1 Trial of ON 123300 for Breast Cancer

Anixa Biosciences, Cleveland Clinic Developing Breast Cancer Vaccine

Subscribe to our mailing list

FDA Gives Breakthrough Device Status to 4D Path’s Breast Cancer Diagnostic Platform

New $100M Program Aims to Improve Diversity in Clinical Trials

FDA Grants Fast Track Status, Rolling Review to Lumicell’s LUM Imaging System

FDA Approves Keytruda-chemo Combo for Advanced TNBC Positive for PD-L1

Breast Cancer Cell Sugars in Liquid Biopsies Could Be Key to Early Detection

Athenex Oncology Offers Free ‘Evidenced-based’ Lifestyle Guide for MBC Patients

Phase 3 Trial to Compare Enhertu to Kadcyla in HER2-Positive, High Risk Patients

FDA Approves FoundationOne Liquid CDx as Companion Diagnostic Test for Piqray Treatment

FDA Grants Fast Track to PC14586, Potential Therapy for Specific p53 Mutation

Adding Ibrance to Hormone Therapy Fails to Prolong Time Before Cancer Recurs, Trial Shows

COVID-19 Surgery Delays May Mean 2,700 More Breast Cancer Deaths Within 10 Years

Signatera Test for Residual Disease Will Be Used in New Phase 2 Breast Cancer Trial

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

MammaCare Foundation Offers Simulator Training for Manual Breast Exams

FDA Puts Eganelisib on Fast Track for Advanced Triple-negative Breast Cancer

Activities Abound for Breast Cancer Awareness Month

Verzenio With Endocrine Therapy Can Lower Risk of Recurrence, Spread in Early Breast Cancer, Trial Shows

Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

TTC-352 Safe for Patients Resistant to Hormone Therapy, Phase 1 Trial Finds

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

Tesetaxel With Reduced-dose Capecitabine Improved Progression-free Survival in Metastatic Breast Cancer

FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

Phase 2 Trial Launched to Test CFI-400945 Plus Imfinzi in Advanced TNBC

Tecentriq-Chemotherapy Combo Falls Short in TNBC Phase 3 IMpassion131 Trial

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

Tukysa Combo Approved in Australia for Advanced HER2-Positive Breast Cancer

FDA Will Review Two New Applications Seeking Keytruda Approval for TNBC

Fewer, Higher Doses of Radiation Therapy Safe for Early Breast Cancer

Devyser’s Gene Screening Test for Breast, Ovarian Cancers Approved in Europe

EU Certifies Software That Assesses Short-term Breast Cancer Risk